Wilson’s disease and hepatic copper metabolism
Vivet Therapeutics is involved in clinical research for Wilson’s disease, with interest in treatments aimed at correcting the underlying copper transport defect and its impact on liver function. The sponsor’s work reflects a focus on rare inherited disorders affecting metabolic regulation and organ damage.
- Gene therapy for inherited metabolic disease
- Hepatic disease linked to copper accumulation
- Adult patient treatment in rare disease
The clinical portfolio includes research centered on rare genetic liver disorders and therapeutic strategies intended to address disease mechanisms at the molecular level.
Healthy volunteer immunology and AAV neutralising antibodies
The sponsor also studies healthy male volunteers with circulating neutralising antibodies against adeno-associated virus vectors, supporting research relevant to gene transfer eligibility and vector-related immune responses.
- AAV immunogenicity
- Vector-directed antibody screening
- Healthy volunteer safety research
This area of interest is closely tied to gene therapy development and the assessment of immune factors that may influence treatment access and response.
Gene therapy and rare disease medicine
Vivet Therapeutics’ clinical activity is concentrated in genetic medicine, with an emphasis on therapies designed for monogenic disorders and other orphan diseases. Its research landscape includes approaches that target disease biology rather than symptomatic management alone.
- Monogenic disorder treatment
- Orphan disease therapeutics
- Intravenous gene delivery
The sponsor’s trial activity indicates sustained involvement in advanced therapeutic modalities for conditions with limited established treatment options.
